RxDoctor Payments Data

Malcolm Brand, MD

Cardiology · Ithaca, NYNPI 1770507683

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 45.8% of the total.

$5,412in general payments, 2019–2025

Across 102 payments — averaging $53.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Biotronik Inc.$2K
  • Impulse Dynamics (USA) Inc.$164
  • Boehringer Ingelheim$128
  • Abbott$93
  • Edwards Lifesciences$80
  • plus $370 from 11 others

What the payments were for

  • Travel & lodging$2,55647%
  • Food & beverage$2,72050%
  • Education$1363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,412 in reported general payments places this provider in the 80th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$259,803
Medicare patients
919
Services billed
3,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$264,726
EntrestoSacubitril/Valsartan62$101,672
JardianceEmpagliflozin35$51,683
XareltoRivaroxaban24$32,251
Repatha SyringeEvolocumab15$22,918
BrilintaTicagrelor17$19,212
Repatha SureclickEvolocumab11$16,772
Dofetilide17$7,971
Metoprolol Succinate271$6,320
Ezetimibe62$2,303
Atorvastatin Calcium190$2,115
Amiodarone Hcl54$1,774
Flecainide Acetate36$1,193
Rosuvastatin Calcium59$1,034
Losartan Potassium57$829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$264,726198 claims
NovartisEntresto$37$101,67262 claims
Boehringer IngelheimJardiance$128$51,68335 claims
Johnson & JohnsonXarelto$14$32,25124 claims
AstraZenecaBrilinta$38$19,21217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 cardiology providers in New York.

Other cardiology in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →